Fiji

Tuberculosis profile

Population 2018 <1 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>0.48 (0.37–0.61)</td>
<td>54 (42–69)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.025 (0.014–0.04)</td>
<td>2.9 (1.6–4.5)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>&lt;0.01 (&lt;0.01–0.01)</td>
<td>0.35 (0.2–0.54)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.038 (0.037–0.038)</td>
<td>4.2 (4.2–4.3)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>&lt;0.01 (&lt;0.01–0.01)</td>
<td>0.6 (0.31–0.97)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases 0.68%
Previously treated cases 0% (0–34)

TB case notifications, 2018

Total new and relapse 385
- % tested with rapid diagnostics at time of diagnosis 95%
- % with known HIV status 89%
- % pulmonary 68%
- % bacteriologically confirmedººº 55%
- % children aged 0-14 years 20%
- % women 34%
- % men 46%
Total cases notified 389

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 80% (63–100)
TB patients facing catastrophic total costs, 2017 40% (33–47)
TB case fatality ratio (estimated mortality/estimated incidence), 2018 9% (7–11)

TB/HIV care in new and relapse TB patients, 2018

Number (%) Patients with known HIV status who are HIV-positive
- on antiretroviral therapy 18 5%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
- New cases 110%
- Previously treated cases 100%

Laboratory-confirmed cases*

Patients started on treatment* **

MDR/RR-TB 1; XDR-TB 0

MDR/RR-TB cases tested for resistance to second-line drugs

0

Treatment success rate and cohort size

Success Cohort
New and relapse cases registered in 2017 81% 352
Previously treated cases, excluding relapse, registered in 2017 86% 7
MDR/RR-TB cases started on second-line treatment in 2016 100% 1
XDR-TB cases started on second-line treatment in 2016 0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment 100%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100%

TB financing, 2019

National TB budget (US$ millions) 1.3

Funding source: 80% domestic, 2% international, 19% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
*
Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-10-18 Data: www.who.int/tb/data